Jeroen Bakker

Jeroen Bakker is a Partner at Novo Holdings, specifically in the Seed Investments department. He joined Novo Holdings in September 2018, initially as a Principal, and has since been promoted to Partner.12

Jeroen has an extensive background in biotech and venture capital:

Education and Early Career

• PhD in Immunology from the University of Amsterdam
• MSc in Biomedical Sciences from Leiden University, with a specialization in entrepreneurship
• BSc from the Technical University of Delft
• Research Fellow at the La Jolla Institute for Allergy and Immunology in San Diego

Professional Experience

Before joining Novo Holdings, Jeroen worked at:

• M Ventures (corporate venture capital arm of Merck) focusing on Seed and Series A investments
• Various operational biotech roles in companies like Syntaxin (acquired by Ipsen), Inthera, and ISD Immunotech

Current Responsibilities

At Novo Holdings, Jeroen:

• Holds several board positions
• Led investments in companies such as Adcendo and Rappta Therapeutics
• Focuses on identifying, building, and investing in innovative life science startups, particularly in the Nordic region

Board Positions

Jeroen currently serves on the boards of:

• Adcendo
• BiOrigin
• Rappta Therapeutics
• Antag Therapeutics

He previously held board positions at ISD-Immunotech and served as Interim Chief Business Officer there.2

Additional Information

Jeroen has also been involved in academic and professional organizations:

• Chair of the Dutch Platform for Young Researchers in Nephrology
• Member of REBBLS, a Danish networking organization for young biotech entrepreneurs

His LinkedIn username is indeed jeroenbakker, as mentioned in the query.2